National Advisory Committee on Immunization (NACI)

About NACI

NACI is a national committee of recognized experts in the fields of pediatrics, infectious diseases, immunology, medical microbiology, internal medicine and public health. The Committee reports to the Chief Public Health Officer of Canada, and works with departmental staff of the Centre for Infectious Disease Prevention and Control (CIDPC) of the Public Health Agency of Canada to provide ongoing and timely medical, scientific and public health advice.

NACI makes recommendations for the use of vaccines currently or newly approved for use in humans in Canada, including the identification of groups at risk for vaccine-preventable disease for whom vaccine programs should be targeted. All NACI recommendations on vaccine use in Canada are published every four years in the Canadian Immunization Guide. Additional statements and updates are published in the Canada Communicable Disease Report (CCDR). NACI also advises on the need for national vaccination strategies and makes recommendations for vaccine development research.

Contact us

NACI@phac-aspc.gc.ca

Meetings

February 4-5, 2009, Ottawa, Ontario

Past Meetings:

October 15-16, 2008, Ottawa, Ontario
June 4-5, 2008, Ottawa, Ontario
February 6-7, 2008, Ottawa, Ontario
October 10-11, 2007, Ottawa, Ontario
June 6-7, 2007, Ottawa, Ontario
February 7-8, 2007, Ottawa, Ontario
October 4-5, 2006 Ottawa, Ontario
May 31-June 1 2006 Vancouver, British Columbia
February 7-9, 2006 Ottawa, Ontario

Recent Statements (in order by date)

2009

• Evidence-based recommendations for immunization – Methods of the National Advisory Committee on Immunization

2008

• Statement on the recommended use of pneumococcal 23-valent polysaccharide vaccine in homeless persons and injection drug users
• Statement on Influenza Vaccination for the 2008-2009 Season
• Canadian Immunization Guide Seventh Edition - 2006 - Notice
  • Guide Errata and Clarifications, March 2008
  • Table on Vaccines Currently Approved for Use in Canada, updated as of March 2008
• Statement on the recommended use of pentavalent human-bovine reassortant rotavirus vaccine - January 2008

2007

• Meningococcal C Conjugate for Infants statement- November 2007
• Statement on Mumps Vaccine - 1 August 2007
• Statement on Influenza Vaccination for the 2007-2008 Season - 1 July 2007
• Addendum Posted: 2007-10-16
• Thimerosal: Updated Statement - 1 July 2007
• Statement on Conjugate meningococcal Vaccine for Serogroups A,C, Y and W135 - 1 May 2007
• Statement on Human Papillomavirus Vaccine - 15 February 2007
• Statement on the recommended use of pentavalent and hexavalent vaccines - 1 February 2007

2006

• Varizig™ as the Varicella Zoster immune globulin for the prevention of Varicella In at-risk patients - 15 October 2006
• Statement On Influenza Vaccination for The 2006-2007 Season
  - 15 June 2006
  • Erratum
• Update On the Recommendations For The Routine Use of Pneumococcal Conjugate Vaccine For Infants - 1 May 2006
• Update on Influenza Vaccination For The 2005-2006 Season - 1 March 2006

2005

• Updated Recommendations on the use of Thimerosal-Containing Vaccines in Canada - 1 December 2005
• Update on Influenza Vaccination for the 2005-2006 Season - 1 November 2005
• Interval Between Administration of Vaccines Against Diphtheria, Tetanus, and Pertussis - 15 October 2005
• Statement on Influenza Vaccination for the 2005-2006 Season - 15 June 2005
• Update on Rabies Vaccines - 1 June 2005
• Update on Meningococcal C Conjugate Vaccines - 15 April 2005

Literature Reviews

• Literature review on HPV 6, 11, 16 and 18: Disease and Vaccine Characteristics
• Literature Review on DTaP Based Penta-and Hexavalent Vaccines Approved for Clinical Use in Canada, October 2006